Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...
The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer. The oral drug ...
See something others should know about? Email CHS or call/txt (206) 399-5959. You can view recent CHS 911 coverage here. Hear sirens and wondering what’s going on? Check out reports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results